January
Lonza started 2019 by announcing record-breaking full-year 2018 results in a major transformational year
Lonza commenced commercial supply of Portola’s second-generation Andexxa®
Lonza announced the succession of the CEO
February
Lonza strengthened Pharma Biotech & Nutrition offerings with aligned structure
DuPont Nutrition and Health, and Lonza Specialty Ingredients announced a joint agreement in human milk oligosaccharides
March
Lonza completed divestment of its Water Care business
Lonza provided adjusted Mid-Term Guidance 2022 to reflect the divestment of its former Water Care business unit
Sheba and Lonza to collaborate on Cocoon™ platform bringing automated cell-therapy manufacturing to the clinic
April
Lonza and Chr. Hansen created a strategic joint venture to become the partner of choice for developing and manufacturing live biotherapeutic products for pharma and biotech customers
May
Alector opted for Lonza’s Ibex™ Develop to secure future manufacturing for neurodegeneration therapies
June
Lonza announced its intention to proceed with a carve-out of its Specialty Ingredients segment to allow the segment to become a global leader in microbial control
Lonza announced an investment in a major expansion of highly potent active pharmaceutical ingredients (HPAPI) capacity at its Visp (CH) site to meet increased market demand
July
Lonza announced the start of expansion to its bioconjugation facility in Visp (CH), together with the additional antibody drug conjugates (ADCs) produced at the site
Lonza reported continued positive momentum in its core healthcare businesses with organic growth of 6.4% sales and 7.7% CORE EBITDA in H1 2019
August
Lonza acquired a sterile fill and finish facility from Novartis to complement Pharma Biotech & Nutrition current parenteral drug product offering in Basel (CH)
October
Lonza’s Ibex™ Solutions in Visp (CH) to support Genmab’s growing clinical portfolio
Mesoblast and Lonza entered into agreement for commercial manufacture of Mesoblast’s potential first United States allogeneic therapy
November
Board announcement – Albert M. Baehny, Chairman of the Board of Directors, took on the additional responsibility of Chief Executive Officer on an ad interim basis. Christoph Mäder appointed as Lead Independent Director